Nasus Pharma (NSRX) Cash & Current Investments (2024 - 2025)
Nasus Pharma (NSRX) reported Cash & Current Investments of $4.3 million for Q4 2025, up 1409.15% on a YoY basis from $284000.0 in Q4 2024, and up 1747.41% quarter-over-quarter from $232000.0 in Q2 2025.
Nasus Pharma (NSRX) Cash & Current Investments (2024 - 2025) Analysis & Trends
Nasus Pharma has reported Cash & Current Investments for 2 years, with the latest figure at $4.3 million in Q4 2025.
- For the quarter ending Q4 2025, Cash & Current Investments rose 1409.15% year-over-year to $4.3 million; the trailing twelve-month figure through Dec 2025 stood at $4.3 million (up 1409.15% YoY), and the FY2025 full-year result was $4.3 million, up 1409.15% from the prior year.
- Cash & Current Investments for Q4 2025 stood at $4.3 million, up from $232000.0 in the prior quarter.
- The five-year high for Cash & Current Investments was $4.3 million in Q4 2025, with the low at $232000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 4.38 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 5.28 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 22.05 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 9.39 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 5.70 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 12.04 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 7.64 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 13.08 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 10.49 Bn |
| 10 | Nasus Pharma | 23.47 Mn | 19.18 Mn | - | 4.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.29 Mn |
| Jun 30, 2025 | 232,000.00 |
| Dec 31, 2024 | 284,000.00 |